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Plasmodium falciparum merozoite surface 
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Abstract 
Background: The production of properly folded, recombinant sub-unit Plasmodium falciparum malaria vaccine can-
didates in sufficient quantities is often a challenge. Success in vaccine immunogenicity studies in small animal models 
does not always predict immunogenicity in non-human primates and/or human subjects. The aim of this study was 
to assess the immunogenicity of a chimeric blood-stage malaria vaccine in Aotus monkeys. This vaccine candidate 
includes the neutralizing B cell epitopes of P. falciparum merozoite surface protein 1 (rPfMSP119) genetically linked to a 
highly immunogenic, well-conserved P. falciparum merozoite surface protein 8 (rPfMSP8 (ΔAsn/Asp)) partner.
Methods: Aotus nancymaae monkeys were immunized with purified rPfMSP1/8 or rPfMSP8 (ΔAsn/Asp) formulated 
with Montanide ISA 720 as adjuvant, or with adjuvant alone. Antibody responses to MSP119 and MSP8 domains were 
measured by ELISA following primary, secondary and tertiary immunizations. The functionality of vaccine-induced 
antibodies was assessed in a standard P. falciparum blood-stage in vitro growth inhibition assay. Non-parametric tests 
with corrections for multiple comparisons when appropriate were used to determine the significance of differences in 
antigen-specific IgG titres and in parasite growth inhibition.
Results: The chimeric rPfMSP1/8 vaccine was shown to be well tolerated and highly immunogenic with boost-able 
antibody responses elicited to both PfMSP8 and PfMSP119 domains. Elicited antibodies were highly cross-reactive 
between FVO and 3D7 alleles of PfMSP119 and potently inhibited the in vitro growth of P. falciparum blood-stage 
parasites.
Conclusions: Similar to previous results with inbred and outbred mice and with rabbits, the PfMSP1/8 vaccine was 
shown to be highly effective in eliciting P. falciparum growth inhibitory antibodies upon immunization of non-human 
primates. The data support the further assessment of PfMSP1/8 as a component of a multivalent vaccine for use in 
human subjects. As important, the data indicate that rPfMSP8 (ΔAsn/Asp) can be used as a malaria specific carrier pro-
tein to: (1) drive production of antibody responses to neutralizing B cell epitopes of heterologous vaccine candidates 
and (2) facilitate production of properly folded, recombinant P. falciparum subunit vaccines in high yield.
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Background
There have been measurable gains in reducing the global 
burden of malaria through the integration of control 
programmes involving insecticide-treated bed nets, 
indoor residual spraying of pesticides, and intermittent 
preventive therapy [1]. Nevertheless, the malaria bur-
den remains high, with the World Health Organization 
reporting 198 million cases and an estimated 367,000–
755,000 deaths worldwide in 2013. It is expected that the 
addition of an effective malaria vaccine to the battery of 
malaria control strategies would accelerate the decline 
in disease and promote long-term sustainable control. 
RTS,S, the first malaria vaccine to reach phase III clinical 
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trials, is a pre-erythrocytic-stage vaccine based on the 
circumsporozoite protein of Plasmodium falciparum [2]. 
Initial reports suggest that vaccine efficacy may only be 
around 30 % in the most vulnerable target population of 
infants [3], with a higher efficacy of approximately 50 % 
in young children [4], but with concerns regarding the 
durability of protection. The efficacy of other malaria 
vaccine candidates that have been evaluated in phase II 
trials has not been impressive [5–10].
There is mounting agreement in the field that an effec-
tive malaria vaccine will require induction of immune 
responses to multiple, distinct target antigens. This con-
cept is central in the development of whole parasite-based 
vaccines, including radiation (PfSPZ) [11, 12] and geneti-
cally (PfGAS) [12–14] attenuated sporozoite vaccines, 
infection-treatment pre-erythrocytic-stage vaccines [15, 
16], and chemically inactivated whole blood-stage vac-
cines [17, 18]. However, these whole parasite approaches 
face significant challenges related to production, formu-
lation, standardization, delivery, and safety that are less 
problematic for sub-unit-based vaccines. Other signifi-
cant challenges associated with sub-unit malaria vac-
cine development have been encountered. These include 
difficulties in producing properly folded candidate anti-
gens, polymorphism in T and B cell epitopes, and poor 
immunogenicity. Several years ago while working in the 
Plasmodium yoelii model, the additional problem of anti-
genic competition was encountered when combining just 
two blood-stage vaccine components, merozoite surface 
protein 1 (MSP142) and MSP8 [19]. This problem has also 
impeded the development of other multi-antigen malaria 
vaccine formulations [20–24].
For sub-unit malaria vaccines, a well-established strat-
egy to enhance the immunogenicity of neutralizing B 
cell epitopes was adopted, namely the use of a highly 
immunogenic carrier protein. Taking advantage of the 
immunogenicity of MSP8, a chimeric protein with the 
conformational, protective B cell epitopes of MSP119, 
fused to MSP8 was generated. Immunization with the 
chimeric rPyMSP1/8 vaccine induced high and compa-
rable antibody responses against both PyMSP119 and 
PyMSP8, resulting in nearly complete protection against 
lethal P. yoelii 17XL malaria [19]. The enhanced efficacy 
of the rPyMSP1/8 vaccine, in comparison to a combined 
formulation of rPyMSP142 and rPyMSP8, was not due to 
an improved conformation of protective B cell epitopes 
or the generation of novel epitopes in the chimeric mole-
cule [19, 25]. The key finding was that immunization with 
rPyMSP1/8 elicited an MSP8-restricted T cell response 
that provided effective help for both PyMSP119 and 
PyMSP8 specific B cells to produce high and sustained 
levels of protective antibodies [25].
Based on the proof-of-concept studies in the P. yoelii 
model, P. falciparum MSP8 was pursued as a parasite-
specific carrier protein to overcome challenges associated 
with the production of recombinant antigen vaccines 
(quality, yield) and with the sub-optimal immunogenicity 
of relevant neutralizing B cell epitopes [26, 27]. Among 
different P. falciparum isolates, MSP8 is highly con-
served, exhibiting 95  % amino acid identity with slight 
variations in an N-terminal Asn/Asp-rich domain [28]. 
The remaining C-terminal sequence is invariant. Fol-
lowing codon harmonization [29] and genetic fusion of 
PfMSP119 and PfMSP8 (ΔAsn/Asp) coding sequences, a 
properly folded chimeric antigen was produced in high 
yield, utilizing an Escherichia coli expression system 
[27]. Immunogenicity studies in both inbred and outbred 
mice demonstrated a strong T cell response restricted to 
epitopes within PfMSP8 sequence and the production 
of high titres of antibodies to both MSP119 and MSP8 
domains. Comparable PfMSP1/8 immunogenicity stud-
ies in rabbits demonstrated the induction of high titres of 
PfMSP119 specific antibodies that very effectively inhib-
ited the in vitro growth of P. falciparum parasites of both 
the 3D7 and FVO strains. While these data are encourag-
ing, results of vaccine studies in mice and rabbits do not 
always predict outcomes upon immunization of human 
subjects. In this study, the immunogenicity of PfMSP1/8 
was evaluated in non-human primates, assessing the 




The production and purification of the chimeric 
rPfMSP1/8 and rPfMSP8 (ΔAsn/Asp) (P. falciparum FVO 
strain) followed the same protocol, using codon-har-
monized, synthetic gene sequences cloned into pET-28 
(EMD Biosciences, San Diego, CA, USA) and SHuffle™ 
T7 Express lysY E. coli cells (New England Biolabs, 
Ipswich, MA, USA) as host. Expression of the recom-
binant proteins was accomplished using a BioFLo115 
bench-top bioreactor (New Brunswick Scientific, Edison, 
NJ, USA). Protocols for the expression and purification 
of recombinant antigens have been reported previously 
[26, 27]. For this study, rPfMSP1/8 and rPfMSP8 (ΔAsn/
Asp) were further purified by gel filtration (Superdex 75, 
GE Healthcare Bio-Sciences Corp, Piscataway, NJ, USA) 
followed by a second round of Ni–NTA affinity chroma-
tography (Qiagen, Valencia, CA, USA). The eluted mate-
rial was dialyzed into 20  mM Tris–HCl, pH 7.2, 0.5  M 
NaCl. The final preparations of rPfMSP1/8 and rPfMSP8 
(ΔAsn/Asp) were filter sterilized (0.22 µm), aliquoted and 
stored at −80  °C. The final protein concentration was 
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determined by bicinchoninic acid protein assay (BCA; 
Thermo Scientific, Rockford, IL, USA). Endotoxin lev-
els were quantitated using the ToxinSensor Chromog-
enic LAL Endotoxin Assay (GenScript, Piscataway, NJ, 
USA). Protein purity and conformation were assessed by 
Coomassie blue staining following SDS-PAGE on 10  % 
gels, run under both reduced and non-reduced condi-
tions. Purity (reduced lanes) and  % monomer (doublet, 
non-reduced lanes) were estimated by densitometry 
using ImageJ processing and analysis software [30].
Animals and immunizations
Adult Aotus nancymaae monkeys were housed at a 
Centers for Disease Control (CDC) primate facility, 
fully-accredited by the Association for Assessment and 
Accreditation of Laboratory Animal Care International 
(AAALAC). Animal studies were reviewed, approved 
and conducted in compliance with the Institutional Ani-
mal Care and Use Committee (IACUC) of CDC. Eight-
een Aotus monkeys were stratified according to weight 
and sex into three groups of six animals, which were then 
randomly assigned to vaccine and control groups. On day 
0, groups of animals were immunized by intramuscu-
lar injection (0.5 ml) of 50 µg of rPfMSP1/8 or rPfMSP8 
(ΔAsn/Asp) emulsified in Montanide ISA 720 (Seppic 
Inc, Paris, France) at a ratio of 70:30 (vol/vol). Control 
animals were immunized with saline/Montanide alone. 
Monkeys were boosted on day 28 and on day 84 with the 
same antigen/adjuvant formulation that was used for the 
priming immunization.
Safety assessment
All monkeys were in good health, free of tuberculosis 
and weighed between 0.8 and 1.2  kg at the start of the 
study. Animals were weighed at weekly intervals. Blood 
and serum were collected at biweekly intervals begin-
ning 2 weeks prior to the first immunization and until the 
completion of the study. Immunization sites were moni-
tored continuously for adverse local reactions. Systemic 
reactions were evaluated by monitoring a panel of hae-
matologic parameters and serum chemistry values that 
included measurements of white blood cells, red blood 
cells, haemoglobin, haematocrit, platelets, blood urea 
nitrogen, glucose, alkaline phosphatase, total protein, ala-
nine aminotransferase, and creatinine.
Measurement of antigen‑specific antibody responses 
by ELISA
Antigen-specific antibody responses induced by immu-
nization with rPfMSP1/8 and rPfMSP8 (ΔAsn/Asp) 
were measured by ELISA as previously described [27]. 
Plates were coated with 0.25  µg per well of purified 
rPfMSP1/8, rPfMSP8 (ΔAsn/Asp), rGST-PfMSP19 (FVO) 
or rGST-PfMSP19 (3D7). Pre-immune sera and sera col-
lected 2 weeks following primary, secondary and tertiary 
immunizations were serially diluted twofold starting at 
1:1250. Bound antibodies were detected using horse-
radish peroxidase conjugated goat anti-Aotus IgG [31] 
diluted 1:7500 and with ABTS [2,2′-azinobis(3-ethylb-
enzthiazolinesulfonic acid)] as substrate. A405 values 
between 1.0 and 0.1 were plotted and titre calculated as 
the reciprocal of the dilution that yielded an A405 of 0.5. 
A high titre pool of serum obtained from rPfMSP1/8 
immunized monkeys (n  =  5) was included on each 
assay plate as an internal reference to normalize the data 
between assays. Pre-immune sera were used to establish 
background reactivity of each animal to each antigen and 
subtracted as background.
Plasmodium falciparum growth inhibition assays
The growth inhibitory activity (GIA) of protein G puri-
fied IgG from rPfMSP1/8 to rPfMSP8 (ΔAsn/Asp) 
immunized and adjuvant control monkeys was assessed 
in vitro by the measurement of parasite lactate dehydro-
genase activity [32] using standard protocols. Pre-bleed 
and adjuvant control IgG served as negative controls. 
Immune IgG was tested at a concentration of 10 mg/ml. 
GIA was calculated relative to P. falciparum FVO blood-
stage parasites growing in complete media in the absence 
of any added Aotus IgG.
Statistical analysis
When comparing data from two groups, the statistical 
significance of the differences in antigen-specific IgG 
titres or parasite growth inhibition was determined by 
the Mann–Whitney test. The statistical significance of 
increases in antigen-specific titres between paired pri-
mary, secondary and tertiary immunization sera was 
determined using the Friedman test followed by Dunn’s 
multiple comparison correction. Probability (p) val-
ues ≤ 0.05 were considered significant.
Results
The production and purification of rPfMSP1/8 and 
rPfMSP8 (ΔAsn/Asp) was reported previously [26, 27]. 
Figure 1 shows a Coomassie-blue stained polyacrylamide 
gel of reduced (lanes 1 and 2) and non-reduced (lanes 3 
and 4) purified recombinant antigens used in this Aotus 
immunogenicity study. As previously observed, the two 
recombinant vaccine antigens migrate as a predomi-
nant doublet in the absence of reducing agent [26, 27]. 
Purity of the final product was estimated to be 93–94 % 
with ≥85 % monomer. Endotoxin levels in the final vac-
cine preparation were less than 1 EU/mg of protein. 
Prior studies showed that immunization of Aotus mon-
keys with rPfMSP142 elicited antibodies that inhibited 
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the in  vitro growth of P. falciparum blood-stage para-
sites [31]. rPfMSP142 vaccines formulated with Com-
plete Freund’s adjuvant elicited higher titres of functional 
antibodies in comparison to formulations with Mon-
tanide ISA 720. For this study, Montanide ISA 720 was 
selected as adjuvant in an effort to balance potency with 
safety. Aotus monkeys (six per group) were immunized 
and boosted twice (days 0, 28 and 84) with 50  µg/dose 
of rPfMSP1/8 or rPfMSP8 (ΔAsn/Asp) formulated with 
Montanide ISA 720 or with adjuvant alone.
Immunization with rPfMSP1/8 or rPfMSP8 (ΔAsn/
Asp) was reasonably well tolerated. Local injection site 
reactions were noted following the second and third 
immunizations (Table  1). These consisted primarily of 
small nodules at the injection site and/or local swelling, 
which typically resolved. Prior to the first immunization, 
baseline haematology and blood chemistry profiles were 
determined for each animal. Subsequently, blood and 
serum were collected biweekly through the course of the 
study for monitoring. Fluctuations from baseline values 
were noted in individual animals across groups. Altera-
tions attributable to a systemic response to a specific vac-
cine formulation were not apparent.
Sera collected 2 weeks after each immunization 
were evaluated by ELISA to determine the titres of IgG 
antibodies specific for the rPfMSP8 (ΔAsn/Asp) car-
rier and for PfMSP119 epitopes of both the FVO and 
3D7 alleles (Fig. 2). Immunization with rPfMSP8 (ΔAsn/
Asp) or rPfMSP1/8 elicited comparable IgG responses 
to rPfMSP8 specific epitopes following the primary 
immunization (p  >  0.5). Two additional immunizations 
markedly boosted the rPfMSP8-specific IgG response in 
both groups by  >100-fold (p  <  0.05, primary vs tertiary 
mean titre). Significant titres of antibodies to PfMSP119 
epitopes were not detected in rPfMSP8 (ΔAsn/Asp) 
immunized animals following primary and secondary 
immunization. Following a third immunization with the 
rPfMSP8 (ΔAsn/Asp) carrier, a low titre of antibodies 
cross-reactive with PfMSP119 was detected in two ani-
mals, presumably due to some similarity in the C-termi-
nal EGF-like domains of PfMSP1 and PfMSP8 [33]. In 
contrast, immunization with rPfMSP1/8 induced a strong 
and boost-able antibody response to PfMSP119 that was 
highly cross-reactive between the FVO and 3D7 alleles of 
PfMSP119.
Fig. 1 Purified recombinant chimeric rPfMSP1/8 and rPfMSP8 (ΔAsn/
Asp) vaccine antigens. A Coomassie blue-stained 10 % SDS–poly-
acrylamide gel containing purified rPfMSP1/8 (3 μg, lanes 1 and 3) 
or rPfMSP8 (ΔAsn/Asp) (3 μg, lanes 2 and 4) was run under reducing 
(lanes q and 2) and non-reducing (lanes 3 and 4) conditions. Molecular 
weight markers in kilodaltons (kDa) are shown. Endotoxin levels 
and  % purity for each antigen preparation are also indicated
Table 1 Immunization site reactions
Group I Montanide ISA 720 control
 AI-1944 Small bump above inoculation site, right side follow-
ing first immunization, persisting
 AI-2010 None
 AI-2016 Haemorrhage at venipuncture site, fatal
 AI-2029 None
 AI-2033 Hard knot, right side following third immunization
 AI-2036 None
Group II rPfMSP8 (ΔAsn/Asp) + Montanide ISA 720
 AI-1990 None
 AI-1993 None
 AI-2012 Right thigh slightly swollen, one time point following 
second immunization
 AI-2022 Right thigh slightly swollen, one time point following 
second immunization
 AI-2028 Swollen dime-sized knot, reduced at subsequent 
time point
 T-1048 None
Group III rPfMSP1/8 + Montanide ISA 720
 AI-1924 Right thigh larger, no focus, one time point following 
second immunization
 AI-2006 Left side, large knot, following second immunization, 
persisting




 AI-2031 Right thigh swollen, resolved following second 
immunization
 AI-2035 Right thigh swollen, one time point following second 
immunization
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To assess functionality, antibodies elicited by immu-
nization with rPfMSP8 (ΔAsn/Asp) or rPfMSP1/8 were 
evaluated for the ability to inhibit the in vitro growth of 
P. falciparum blood-stage parasites. As shown in Fig.  3, 
purified IgGs obtained following the third immunization 
of Aotus monkeys with rPfMSP1/8 effectively inhibited 
parasite growth. In contrast, no growth inhibitory activity 
was observed with IgG from rPfMSP8 (ΔAsn/Asp) immu-
nized or adjuvant control animals (p < 0.01). PfMSP8 is 
not believed to be a significant target of growth inhibi-
tory antibodies due to its low and transient expression 
on the merozoite surface [26, 34]. These data from Aotus 
monkeys are also consistent with the previous findings in 
antigen reversal assays, demonstrating that the inhibitory 
activity of rabbit anti-rPfMSP1/8 IgG was due to antibod-
ies specific for PfMSP119 epitopes [27]. However, there 
was no correlation between GIA and the magnitude of 
the antibody response to rPfMSP1/8, rPfMSP8 (ΔAsn/
Asp) or rPfMSP119 in rPfMSP1/8 immunized animals. As 
such, the fine specificity of the PfMSP119 response and/
or a potential interaction between PfMSP119 and PfMSP8 
specific antibodies may be a factor.
Following immunization, rPfMSP8 (ΔAsn/Asp), 
rPfMSP1/8 and adjuvant control groups were challenged 
intravenously with 50,000 P. falciparum FVO parasitized 
red blood cells (pRBCs). Three rPfMSP8 (ΔAsn/Asp) 
immunized animals developed moderate parasitaemia 
(<200,000 pRBC/µl) and self-cured. The remaining three 
animals in this group developed high-density parasitae-
mia (>200,000 pRBC/µl) requiring drug treatment to 
clear the infection. Similarly, three rPfMSP1/8 immu-
nized animals controlled parasitaemia (<200,000 pRBC/
µl), with two of these clearing their infection and one 
requiring drug treatment due to anaemia. In the Monta-
nide control group, three animals developed high-density 
parasitaemia (>200,000 pRBC/µl) and were drug treated 
to clear the infection. However, the remaining two adju-
vant control animals exhibited greatly extended prepatent 
periods, developed unexpectedly low peak parasitaemia 
Fig. 2 Specificity of antibody response induced by immunization with rPfMSP8 (ΔAsn/Asp) versus rPfMSP1/8 vaccines. Antigen-specific IgG titres 
(mean ± standard deviation) in sera collected from Aotus monkeys (6 animals/group) immunized with a rPfMSP8 (ΔAsn/Asp) or b rPfMSP1/8 vac-
cines formulated with Montanide ISA 720 were determined by ELISA. Sera collected 2 weeks following primary, secondary and tertiary immuniza-
tion were evaluated. ELISA plates were coated with either rPfMSP1/8, rPfMSP8 (ΔAsn/Asp), rGST-PfMSP119 (FVO), or rGST-PfMSP119 (3D7) as indicated. 
For each animal, reactivity of pre-immunization serum was subtracted as background
Fig. 3 In vitro inhibition of Plasmodium falciparum growth by Aotus 
IgG induced by immunization with rPfMSP8 (ΔAsn/Asp) versus 
rPfMSP1/8 vaccines. In vitro growth inhibitory activity of IgG from 
immunized Aotus monkeys for P. falciparum FVO blood-stage para-
sites was based on measurement of parasite lactate dehydrogenase 
levels. Purified IgG (10 mg/ml) from animals immunized three times 
with Montanide alone (n = 6), rPfMSP8 (ΔAsn/Asp) + Montanide 
(n = 5) or rPfMSP1/8 + Montanide (n = 5) was evaluated. Two 
immunized animals (1 rPfMSP8 (ΔAsn/Asp), 1 rPfMSP1/8) tested at 
less than 10 mg/ml of IgG were not included in the Figure. Per cent 
growth inhibition in the presence of Aotus IgG relative to controls in 
the absence of IgG is shown
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(<5000 pRBC/µl) and rapidly self-cured. The reason for 
this large and unusual variability in parasitaemia in the 
control group with this highly virulent strain was not 
apparent. This line of P. falciparum FVO strain in almost 
every previous instance has produced rapidly rising para-
sitaemia in control animals that required drug treatment 
to prevent death. Nevertheless, because of this unex-
pected variability, the ability to draw meaningful conclu-
sions regarding vaccine efficacy was compromised.
In a previous study, Lyon et  al. [31] completed an 
immunogenicity study in Aotus monkeys with rPfMSP142 
formulated with CFA/IFA, AS02A or Montanide 720. 
With the exception of adjuvant choice, immunization 
protocols were similar to the present study with respect 
to immunizing dose, route, number of immunizations, 
and interval between immunizations. However, antibod-
ies elicited by immunization with PfMSP142 formulated 
with AS02A or Montanide 720 only modestly inhib-
ited P. falciparum growth. The induction of more effec-
tive inhibitory antibodies required immunization with 
PfMSP142 formulated with Freund’s adjuvant. In contrast, 
IgG elicited following immunization with the PfMSP1/8 
chimeric vaccine formulated with Montanide ISA 720, 
an adjuvant which has been used in human clinical trials, 
potently inhibited parasite growth (52.0 ± 11.3 %).
These data, in conjunction with prior studies [26, 
27], demonstrate that rPfMSP8 (ΔAsn/Asp) is an effec-
tive malaria-specific carrier protein that elicits strong 
CD4+ T cell help for the production of merozoite neu-
tralizing antibodies to linked PfMSP119 epitopes. The 
potency of rPfMSP8 (ΔAsn/Asp) has been demonstrated 
in mice and rabbits and now in non-human primates 
and does not require Freund’s adjuvant. Upon immuni-
zation of human subjects, similarly strong CD4+  T cell 
responses to provide B cell help are expected as rPfMSP8 
(ΔAsn/Asp) is predicted to contain epitopes that will 
bind with high affinity to multiple HLA class II alleles 
[35]. It is also notable that rPfMSP8 (ΔAsn/Asp) has been 
engineered to facilitate production and purification of 
chimeric antigens at high levels and in native conforma-
tion utilizing readily scalable protocols and procedures. 
By fusing relevant neutralizing B cell epitopes of other 
vaccine candidates to PfMSP8 (ΔAsn/Asp), a con-
served, highly immunogenic P. falciparum-specific car-
rier protein, it may be possible to similarly to overcome 
challenges associated with the production of recombi-
nant antigen vaccines (quality, yield) and sub-optimal 
immunogenicity.
Conclusions
Extending previous work in small animal models, these 
studies now show that the chimeric PfMSP1/8 vaccine is 
highly immunogenic in non-human primates and induces 
potent parasite neutralizing antibodies. These data jus-
tify additional effort to incorporate PfMSP1/8 as a com-
ponent of a multivalent P. falciparum malaria vaccine to 
augment control efforts. rPfMSP8 (ΔAsn/Asp) may have 
broader use as a fusion partner for poorly immunogenic 
and/or difficult to produce sub-unit vaccine candidates.
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